Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.

Front Med (Lausanne) · 2023 · PMC10219231 · PMID 37250628

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

In combination ICPI therapy there was a trend toward improved PFS, however this failed to reach significance [HR 0.86 (95% 0.70–1.06)].

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.